Ultimovacs - FDA Fast Track boosts confidence in UV1
Ultimovacs has received FDA Fast Track designation for its lead cancer vaccine, UV1, as a potential treatment for mesothelioma and builds on the Orphan Drug designation (ODD) already received in this indication. The designation offers a potentially accelerated route to market (if the clinical data continue to be supportive) as Ultimovacs progresses its universal vaccine in combination with checkpoint inhibitors across five indications. This regulatory decision was based on the positive results of the Phase II NIPU trial (reported October 2023), which showed a 27% reduction in risk of death with UV1 treatment compared to control. While management carefully evaluates an optimal path forward (Phase III programme) in mesothelioma, the most significant near-term catalyst remains the Phase II INITIUM results in malignant melanoma (expected March 2024). The company is scheduled to release FY23 earnings on 14 February and will likely provide an update then.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.